MA50532A - Compositions et méthodes pour le traitement de cancers - Google Patents

Compositions et méthodes pour le traitement de cancers

Info

Publication number
MA50532A
MA50532A MA050532A MA50532A MA50532A MA 50532 A MA50532 A MA 50532A MA 050532 A MA050532 A MA 050532A MA 50532 A MA50532 A MA 50532A MA 50532 A MA50532 A MA 50532A
Authority
MA
Morocco
Prior art keywords
cancers
compositions
treatment
methods
Prior art date
Application number
MA050532A
Other languages
English (en)
Inventor
Costa Pinheiro Pedro Filipe Da
Mark Kester
Jeremy Shaw
Original Assignee
Univ Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Patent Foundation filed Critical Univ Virginia Patent Foundation
Publication of MA50532A publication Critical patent/MA50532A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
MA050532A 2017-11-03 2018-11-05 Compositions et méthodes pour le traitement de cancers MA50532A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762581179P 2017-11-03 2017-11-03

Publications (1)

Publication Number Publication Date
MA50532A true MA50532A (fr) 2020-09-09

Family

ID=66332377

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050532A MA50532A (fr) 2017-11-03 2018-11-05 Compositions et méthodes pour le traitement de cancers

Country Status (4)

Country Link
US (1) US20200268665A1 (fr)
EP (1) EP3703653A4 (fr)
MA (1) MA50532A (fr)
WO (1) WO2019090255A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020154716A1 (fr) * 2019-01-26 2020-07-30 University Of Rochester Compositions et méthodes de traitement du cancer de la prostate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102917690B (zh) * 2010-03-19 2016-08-24 麻省理工学院 脂质囊泡组合物和使用方法
EP2654779B1 (fr) * 2010-12-23 2018-02-28 Ludwig Institute for Cancer Research, Ltd. Formulation liposomique de ceramides non-glycosidiques et ses utilisations
WO2012154942A2 (fr) * 2011-05-10 2012-11-15 The Penn State Research Foundation Compositions de liposomes anioniques à teneur en céramide
US8828391B2 (en) * 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
EP2968143B1 (fr) * 2013-03-15 2019-04-24 Memorial Sloan Kettering Cancer Center Inversion resistance a plusieurs medicaments par ceramide
US20150157646A1 (en) * 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
WO2016033527A1 (fr) * 2014-08-29 2016-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulation immunogène par thérapie de privation endocrinienne permettant d'améliorer la sensibilité de cellules tumorales à une lyse à médiation immunitaire
CN104922067A (zh) * 2014-12-08 2015-09-23 上海张江生物技术有限公司 一种载药纳米脂质体、制备方法及用途
MX2018003685A (es) * 2015-09-24 2018-08-15 Univ California Moleculas tipo esfingolipidos sinteticas, farmacos, metodos de su sintesis y metodos de tratamiento.

Also Published As

Publication number Publication date
EP3703653A4 (fr) 2021-09-08
EP3703653A1 (fr) 2020-09-09
US20200268665A1 (en) 2020-08-27
WO2019090255A1 (fr) 2019-05-09

Similar Documents

Publication Publication Date Title
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
MA50877A (fr) Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
MA45563A (fr) Méthodes de traitement du cancer de l'ovaire
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA43374A (fr) Méthodes de traitement de tumeurs malignes
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA48637A (fr) Polythérapies pour le traitement du cancer
MA41119A (fr) Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
MA47719A (fr) Esketamine pour le traitement de la dépression
MA56212A (fr) Compositions et méthodes de traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
IL268814A (en) Preparations and methods for the treatment of cancer
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies